Based on the latest available information, Fintel's data for Invivyd Inc. (IVVD) does not indicate a recent "surge" in its stock price. In fact, as of August 6, 2025, the share price showed a decrease of 5.65% from the prior week and a decline of 29.06% over the past year.1
However, there have been several significant developments for Invivyd that could be viewed as positive catalysts, even if they haven't yet translated into a sustained stock surge:
- Advancement of VYD2311 Clinical Program: On October 6, 2025, Invivyd announced that the U.S. FDA cleared its Investigational New Drug (IND) application and provided feedback to advance the REVOLUTION clinical program for VYD2311, a vaccine alternative monoclonal antibody candidate for COVID-19 prevention. This includes the DECLARATION Phase 3 pivotal clinical trial and the LIBERTY clinical trial.2
- Q1 2025 Financial Results and PEMGARDA Performance: In May 2025, Invivyd reported $11.3 million in net product revenue for PEMGARDA™ (pemivibart) in Q1 2025. The company noted a re-acceleration of PEMGARDA revenue in Q2 2025 and reiterated its target for near-term profitability by the end of the first half of 2025.3 PEMGARDA has also shown sustained neutralizing activity against dominant SARS-CoV-2 variants, including LP.8.1 and XEC, which represent over 75% of circulating variants in the U.S..3
- Non-Dilutive Loan Facility: In April 2025, Invivyd secured a $30 million term loan facility with Silicon Valley Bank, providing non-dilutive financing ahead of important anticipated catalysts.4
- Public Offering: In August 2025, Invivyd closed a public offering, raising approximately $57.5 million, which included the full exercise of the underwriter's option to purchase additional shares. This financing was led by RA Capital Management and Janus Henderson Investors.5
- Board Appointment: In March 2025, Ajay Royan, founder of Mithril Capital and a significant long-term holder of Invivyd stock, was appointed to the company's Board of Directors.6
While these are positive developments for the company's long-term prospects, the Fintel data available does not currently reflect a "surge" in the stock price. Investors interested in real-time price movements and more granular data can utilize Fintel's stock price and options flow tools for IVVD.
